CLINICAL RESEARCH

We are advancing first-of-kind in-human clinical research to propel development in the role of NMN-C® and synergetic molecules.


Our pipeline is designed to gather as much diverse data as possible to assess a range of lifespan-associated conditions, including cardiovascular, cognitive, muscular, skin and immune health*.


A first-in-human pharmacokinetic** clinical trial is in progress to evaluate the NAD+ increase in blood using Elevant’s Prime oral NMN capsules. Completion expected Q2 2021.

*Elevant’s NMN-C® has not been demonstrated safe or effective for these purposes

** Statement based on the review of publications on PubMed as of January 1, 2021

SENEQUE'S CLINICAL TRIAL PIPELINE

Skin anti-aging

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

40 participants - 28 days - 5% nmn cream

Completed

Skin health

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

60 participants - 56 days - 2% nmn cream

Completed

Physical capacity and muscle recovery

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
150 participants - 38 days - placebo/NMN 250mg/NMN 500mg

Q4 2021

Tolerance & NAD+ levels

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

 20 participants - 30 days - NMN 400mg

Q3 2021

Pharmacokinetics

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

 24 participants - 30 days - NMN 400mg

Q3 2021

Side by Side NMN vs NR

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

60 days - 100 participants - NMN 500mg/NR 500mg

Q1 2022

Repeated Dose

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
 80 participants - 60 days - placebo/NMN 200mg/NMN 600mg/NMN 1000mg

Q3 2021

Lipid and glucose management

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

80 participants - 120 days - placebo/NMN 800mg

Q3 2021

Severe fatigue management

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
100 participants - 60 days - placebo/NMN 600mg

Q4 2021

Cognitive performance

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
100 participants - 120 days - placebo/NMN 600mg

Q4 2021

Sleep quality

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
40 participants - 30 days - NMN 400mg

Q4 2021

Immune health

Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

200 participants - 120 days - placebo/NMN 600mg

Q1 2022

CLINICAL RESEARCH

We are advancing first-of-kind in-human clinical research to propel development in the role of NMN-C® and synergetic molecules.


Our pipeline is designed to gather as much diverse data as possible to assess a range of lifespan-associated conditions, including cardiovascular, cognitive, muscular, skin and immune health*.


A first-in-human pharmacokinetic** clinical trial is in progress to evaluate the NAD+ increase in blood using Elevant’s Prime oral NMN capsules. Completion expected Q2 2021.

*Elevant’s NMN-C® has not been demonstrated safe or effective for these purposes

** Statement based on the review of publications on PubMed as of January 1, 2021

SENEQUE'S CLINICAL TRIAL PIPELINE

Skin anti-aging


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

40 participants - 28 days - 5% nmn cream

Completed

Skin anti-aging


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

60 participants - 56 days - 2% nmn cream

Completed

Physical capacity and muscle recovery


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
150 participants - 38 days - placebo/NMN 250mg/NMN 500mg

Q4 2021

Tolerance & NAD+ levels


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

 20 participants - 30 days - NMN 400mg

Q3 2021

Pharmacokinetics


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

 24 participants - 30 days - NMN 400mg

Q3 2021

Side by Side NMN vs NR


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

60 days - 100 participants - NMN 500mg/NR 500mg

Q1 2022

Repeated Dose


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
 80 participants - 60 days - placebo/NMN 200mg/NMN 600mg/NMN 1000mg

Q3 2021

Lipid and glucose management


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

80 participants - 120 days - placebo/NMN 800mg

Q3 2021

Severe fatigue management


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
100 participants - 60 days - placebo/NMN 600mg

Q4 2021

Cognitive performance


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
100 participants - 120 days - placebo/NMN 600mg

Q4 2021

Sleep quality


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date
40 participants - 30 days - NMN 400mg

Q4 2021

Immune health


Under preparation
Recruiting
Completed
  • Study design
  • Expected completion date

200 participants - 120 days - placebo/NMN 600mg

Q1 2022